Treatment of childhood kaposiform hemangioendothelioma with sirolimus

Julie Blatt, Joseph Stavas, Billie Moats-Staats, John Woosley, Dean S. Morrell

Research output: Contribution to journalArticle

81 Citations (Scopus)

Abstract

Sirolimus (Rapamune), a mammalian target of Rapamycin (mTOR) inhibitor, which has been used extensively in children following solid organ transplantation, has been demonstrated to have anti-angiogenic activity in pre-clinical models. Limited experience suggests that it may have application to the treatment of vascular lesions. We describe our experience with a 1-year-old female with a kaposiform hemangioendothelioma and Kasabach-Merritt phenomenon who had rapid and dramatic response to sirolimus (0.1mg/kg/day). This case provides further rationale for clinical trials of sirolimus in the treatment of vascular lesions.

Original languageEnglish
Pages (from-to)1396-1398
Number of pages3
JournalPediatric Blood and Cancer
Volume55
Issue number7
DOIs
StatePublished - Dec 2010
Externally publishedYes

Fingerprint

Sirolimus
Blood Vessels
Kasabach-Merritt Syndrome
Therapeutics
Organ Transplantation
Kaposiform Hemangioendothelioma
Clinical Trials

All Science Journal Classification (ASJC) codes

  • Oncology
  • Pediatrics, Perinatology, and Child Health
  • Hematology

Cite this

Treatment of childhood kaposiform hemangioendothelioma with sirolimus. / Blatt, Julie; Stavas, Joseph; Moats-Staats, Billie; Woosley, John; Morrell, Dean S.

In: Pediatric Blood and Cancer, Vol. 55, No. 7, 12.2010, p. 1396-1398.

Research output: Contribution to journalArticle

Blatt, J, Stavas, J, Moats-Staats, B, Woosley, J & Morrell, DS 2010, 'Treatment of childhood kaposiform hemangioendothelioma with sirolimus', Pediatric Blood and Cancer, vol. 55, no. 7, pp. 1396-1398. https://doi.org/10.1002/pbc.22766
Blatt, Julie ; Stavas, Joseph ; Moats-Staats, Billie ; Woosley, John ; Morrell, Dean S. / Treatment of childhood kaposiform hemangioendothelioma with sirolimus. In: Pediatric Blood and Cancer. 2010 ; Vol. 55, No. 7. pp. 1396-1398.
@article{deebf915be774c228476606973ca35b9,
title = "Treatment of childhood kaposiform hemangioendothelioma with sirolimus",
abstract = "Sirolimus (Rapamune), a mammalian target of Rapamycin (mTOR) inhibitor, which has been used extensively in children following solid organ transplantation, has been demonstrated to have anti-angiogenic activity in pre-clinical models. Limited experience suggests that it may have application to the treatment of vascular lesions. We describe our experience with a 1-year-old female with a kaposiform hemangioendothelioma and Kasabach-Merritt phenomenon who had rapid and dramatic response to sirolimus (0.1mg/kg/day). This case provides further rationale for clinical trials of sirolimus in the treatment of vascular lesions.",
author = "Julie Blatt and Joseph Stavas and Billie Moats-Staats and John Woosley and Morrell, {Dean S.}",
year = "2010",
month = "12",
doi = "10.1002/pbc.22766",
language = "English",
volume = "55",
pages = "1396--1398",
journal = "Pediatric Blood and Cancer",
issn = "1545-5009",
publisher = "Wiley-Liss Inc.",
number = "7",

}

TY - JOUR

T1 - Treatment of childhood kaposiform hemangioendothelioma with sirolimus

AU - Blatt, Julie

AU - Stavas, Joseph

AU - Moats-Staats, Billie

AU - Woosley, John

AU - Morrell, Dean S.

PY - 2010/12

Y1 - 2010/12

N2 - Sirolimus (Rapamune), a mammalian target of Rapamycin (mTOR) inhibitor, which has been used extensively in children following solid organ transplantation, has been demonstrated to have anti-angiogenic activity in pre-clinical models. Limited experience suggests that it may have application to the treatment of vascular lesions. We describe our experience with a 1-year-old female with a kaposiform hemangioendothelioma and Kasabach-Merritt phenomenon who had rapid and dramatic response to sirolimus (0.1mg/kg/day). This case provides further rationale for clinical trials of sirolimus in the treatment of vascular lesions.

AB - Sirolimus (Rapamune), a mammalian target of Rapamycin (mTOR) inhibitor, which has been used extensively in children following solid organ transplantation, has been demonstrated to have anti-angiogenic activity in pre-clinical models. Limited experience suggests that it may have application to the treatment of vascular lesions. We describe our experience with a 1-year-old female with a kaposiform hemangioendothelioma and Kasabach-Merritt phenomenon who had rapid and dramatic response to sirolimus (0.1mg/kg/day). This case provides further rationale for clinical trials of sirolimus in the treatment of vascular lesions.

UR - http://www.scopus.com/inward/record.url?scp=78049294338&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78049294338&partnerID=8YFLogxK

U2 - 10.1002/pbc.22766

DO - 10.1002/pbc.22766

M3 - Article

C2 - 20730884

AN - SCOPUS:78049294338

VL - 55

SP - 1396

EP - 1398

JO - Pediatric Blood and Cancer

JF - Pediatric Blood and Cancer

SN - 1545-5009

IS - 7

ER -